Developer docs
API playgroundTry for free, no card

Search company profiles

TheWell Bioscience

Full company profile

uuid000aphb

Namestring
TheWell Bioscience
Legal namestring
TheWell Bioscience Inc.
Websiteurl
thewellbio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

TheWell Bioscience, founded in 2015 and headquartered in Monmouth Junction, New Jersey, is a privately-held biotechnology company (1–10 employees) that develops and sells a proprietary xeno-free (animal origin-free) hydrogel platform for 3D cell culture. Its core product family, VitroGel, is a synthetic, biofunctional extracellular matrix mimic offered in ready-to-use formulations (ORGANOID, STEM, MSC, HEK293, NEURON, EMT) and tunable variants with mechanical stiffness from 10 to 20,000+ Pa and functional ligands (RGD, COL, MMP, IKVAV, YIGSR). The platform is complementary with VitroINK bioinks for 3D bioprinting, RocketCell xeno-free media for organoids/iPSCs/NSCs/hMSCs, CytoGrow recombinant growth factors, VitroPrime culture plates engineered for 3D workflows, and Cyto3D live-dead assay kits, forming an end-to-end xeno-free workflow across hydrogel, media, growth factor, vessel, and downstream analysis layers.

Revenue is generated through three streams: (1) direct sales of consumable products (hydrogels, bioinks, media, growth factors, plates, assay kits) via an e-commerce storefront and direct phone/email ordering with quote-based (non-public) pricing; (2) global distribution through Sartorius Group, which acquired a minority equity stake in April 2024 alongside a cooperation agreement; and (3) international sales through a regional distributor network listed on the company website. Custom solutions services provide additional professional-services revenue for specialized research needs. The company sells to academic researchers (e.g., University of Graz, University of Manchester, Temple University), pharmaceutical/biotech drug discovery teams, stem cell and cell-therapy biomanufacturers, lab-automation/high-throughput screening users, and 3D bioprinting researchers, with adoption evidenced by 370+ peer-reviewed publications citing the products.

Short descriptiontext

TheWell Bioscience is a privately-held New Jersey biotech that develops and sells an end-to-end xeno-free 3D cell culture platform, including VitroGel hydrogels, VitroINK bioinks, RocketCell media, CytoGrow growth factors, VitroPrime plates, and Cyto3D assays, serving academic researchers, pharma/biotech drug discovery teams, and cell-therapy biomanufacturers globally via direct sales, distribution partners, and a Sartorius global distribution partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMonmouth Junction, United States
HQ citystring
Monmouth Junction
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
xeno-free hydrogels, 3D cell culture reagents, organoid culture media, biofunctional bioinks, cell culture plates
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
3D Cell Culture Reagents
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Hydrogel and Bioink Product Sales
TypeOne Time License
Description

TheWell Bioscience generates revenue primarily through the direct sale of its proprietary xeno-free hydrogel products (VitroGel®), bioinks (VitroINK®), culture media (RocketCell™), culture vessels (VitroPrime™), growth factors (CytoGrow™), assay kits, and cell recovery solutions. Products are sold via e-commerce, direct sales, and distributor networks globally.

thewellbio.com
2Distribution Agreement Revenue (Sartorius)
TypeOne Time License
Description

Sartorius Group distributes TheWell Bioscience's products globally under a cooperation agreement, providing TheWell with expanded market reach and revenue from distribution arrangements.

thewellbio.com
3Custom Solutions Services
TypeProfessional Services
Description

The company offers custom solutions services for specialized research needs, indicating revenue from service engagements alongside product sales.

thewellbio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1VitroGel®
Description

Xeno-free biofunctional hydrogel system for 3D cell culture applications including organoids, stem cells, and bioprinting

thewellbio.com
+5 more records
Core offering1 text field

TheWell Bioscience develops, manufactures, and sells an end-to-end, xeno-free (animal origin-free) 3D cell culture platform built around its proprietary VitroGel® biofunctional hydrogel technology. The product portfolio spans hydrogels (VitroGel®), 3D bioprinting bioinks (VitroINK®), xeno-free culture media (RocketCell™), recombinant growth factors (CytoGrow™), culture plates and vessels (VitroPrime™), live/dead assay kits (Cyto3D®), cell/organoid recovery solutions, and assay kits for angiogenesis, cell invasion, and glioblastoma research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Complete ECM dissociation within 2 minutes with VitroGel Organoid Recovery Solution vs. over an hour for conventional alternatives
+3 more records
Product overview1 text field

TheWell Bioscience offers an end-to-end, xeno-free 3D cell culture platform consisting of multiple integrated product families. The core offering centers on VitroGel® hydrogels—a range of animal-free, biofunctional hydrogel systems for 3D cell culture available in ready-to-use and tunable formulations. Complementary products include VitroINK® bioinks for 3D bioprinting, RocketCell™ xeno-free culture media for diverse cell types (organoids, iPSCs, NSCs, hMSCs), CytoGrow™ recombinant growth factors and proteins, VitroPrime™ culture plates and vessels optimized for 3D workflows, and Cyto3D® downstream analysis reagents. The platform is designed for applications including organoid culture, stem cell scale-up, cancer research, drug discovery, lab automation, and biomanufacturing. The company positions itself as an all-in-one xeno-free biofunctional platform for precision medicine, cell therapy, and biomanufacturing.

Product and service5 records
1VitroGel® Hydrogel System
Category3D Cell Culture Hydrogels
Description

Xeno-free, biofunctional hydrogel matrix that mimics natural extracellular matrix for 3D cell culture. Available in ready-to-use variants (ORGANOID, STEM, MSC, HEK293, NEURON, EMT) and tunable variants (3D, RGD, COL, MMP, IKVAV, YIGSR) with adjustable mechanical strength and functional ligands. Enables 3D cell culture assays in less than 20 minutes.

2VitroINK® Bioinks
Category3D Bioprinting Bioinks
Description

Xeno-free, biofunctional bioink for 3D bioprinting that prints without UV, heat curing, or chemical cross-linking. Available in multiple functional ligand variants (3D, RGD, COL, MMP, IKVAV, YIGSR) with corresponding starter kits, mixing kits, nozzle tips, and needle tips.

3RocketCell™ Xeno-Free Culture Media
CategoryCell Culture Media
Description

Portfolio of xeno-free 3D cell culture media supporting diverse cell culture applications including organoids, iPSCs, NSCs, and hMSCs. Includes specialized media for organoid culture, iPSC expansion and differentiation, MSC culture, and neural stem cell applications.

4CytoGrow™ Recombinant Growth Factors and Proteins
CategoryRecombinant Proteins
Description

Portfolio of premium-grade recombinant proteins including growth factors (EGFs, FGFs, PDGFs, TGFs, VEGFs, IGFs, interferons, interleukins), extracellular matrix proteins (fibronectin, vitronectin), and accessory proteins for cell culture applications requiring bioactivity and lot-to-lot consistency.

5VitroPrime™ Culture Plates and Vessels
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1PeptiGrowth Inc.
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-01-07
Description

TheWell Bioscience and PeptiGrowth entered into a Marketing Collaboration Agreement to jointly promote complementary cell culture technologies. The partnership combines TheWell's xeno-free VitroGel® hydrogel system with PeptiGrowth's synthetic peptide growth factors to offer a complete xeno-free workflow solution for researchers and biomanufacturers in global life science markets.

prnewswire.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-09
Description

Sartorius Group entered into a cooperation agreement and minority shareholding investment in TheWell Bioscience. Under the agreement, Sartorius distributes TheWell Bioscience's animal-free hydrogels and bioinks globally, aiming to improve predictions in drug discovery. The partnership combines Sartorius's global distribution reach with TheWell's xeno-free hydrogel technology. Legal advisory was provided by Hogan Lovells for the cross-border transaction.

3Dr. Eva Roblegg's Group, University of Graz
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic research collaboration where Dr. Roblegg's group at the University of Graz used VitroGel® to develop an advanced in vitro vascularized intestinal model including macrovascular endothelium, published in Molecular Pharmaceutics.

thewellbio.com
4Breast Biology Group, University of Manchester
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration with the Breast Biology Group at the University of Manchester's Breast Centre to develop a novel preclinical explant model of the normal human breast using VitroGel® RGD, funded by Prevent Breast Cancer and published in the Journal of Mammary Gland Biology and Neoplasia.

thewellbio.com
5PAL Lab, Temple University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

The PAL Lab at Temple University, led by Ajay Pal, Ph.D., initiated research on VitroGel® NEURON for spinal cord injury repair applications.

thewellbio.com
Strategic tierMinorTypeOthers
Description

Hogan Lovells provided legal advisory services to Sartorius Group for the cooperation agreement and minority shareholding in TheWell Bioscience, handling multiple legal and strategic considerations for the cross-border transaction.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Corning Incorporated
TypeBroad incumbent
Description

Corning manufactures Matrigel, the dominant animal-derived ECM benchmark that TheWell's VitroGel platform directly competes against in 3D cell culture and organoid applications. Comparable because Corning also produces plastic labware, cell culture vessels, and bioprocess consumables, serving overlapping pharma and academic customers.

TypeBroad incumbent
Description

Thermo Fisher offers Gibco cell culture media, growth factors, and 3D culture reagents across its life sciences portfolio. Comparable because it sells overlapping reagents and consumables to the same pharma, biotech, and academic researchers that TheWell targets, with far broader bundling and distribution leverage.

3Merck KGaA (MilliporeSigma)
TypeBroad incumbent
Description

MilliporeSigma supplies ECM hydrogels, cell culture media, and bioprocess reagents under the Sigma-Aldrich brand. Comparable because it serves the same 3D cell culture, organoid, and cell therapy manufacturing markets with a much larger commercial and regulatory footprint.

TypeDirect peer
Description

STEMCELL Technologies develops specialized cell culture media, reagents, and tools for stem cell, organoid, and immunology research. Comparable because it targets the same life sciences researcher customer base with overlapping product categories (media, matrices, differentiation kits) and competes head-to-head with RocketCell and VitroGel.

TypeDirect peer
Description

BICO, through CELLINK and its subsidiaries, provides bioinks, 3D bioprinters, and tissue engineering consumables. Comparable because it offers VitroINK's direct competition in xeno-free bioinks and operates in overlapping 3D bioprinting and tissue engineering customer segments.

6Advanced BioMatrix
TypeDirect peer
Description

Advanced BioMatrix manufactures collagen-based, hyaluronic acid, and synthetic ECM hydrogels for 3D cell culture and bioprinting. Comparable because it sells directly overlapping hydrogel and bioink products targeting the same 3D cell culture and tissue engineering researchers.

TypeEmerging player
Description

TissUse develops multi-organ-on-chip and microphysiological systems for drug testing and disease modeling. Comparable because it serves overlapping preclinical researchers using 3D cell models and complements or competes with organoid-based workflows that VitroGel enables.

TypeDirect peer
Description

Reprocell provides stem cell products, 3D cell culture reagents, and custom bioassay services to pharma and academic researchers. Comparable because it sells directly competing cell culture matrices and reagents to the same iPSC, organoid, and drug discovery customer segments.

TypeEmerging player
Description

Organovo develops 3D bioprinted human tissue models for drug discovery and therapeutic applications. Comparable because it operates in the 3D bioprinting and tissue engineering space served by VitroINK and intersects with TheWell's organoid and tissue modeling customer base.

10PeptiGrowth
TypeOthers
Description

PeptiGrowth develops synthetic peptide growth factors for cell culture and regenerative medicine. Comparable as an ecosystem partner through the 2026 marketing collaboration with TheWell, addressing overlapping stem cell and cell therapy manufacturing customers seeking a fully xeno-free workflow.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TheWell Bioscience

3D Cell Culture Reagentsthewellbio.com

TheWell Bioscience is a privately-held New Jersey biotech that develops and sells an end-to-end xeno-free 3D cell culture platform, including VitroGel hydrogels, VitroINK bioinks, RocketCell media, CytoGrow growth factors, VitroPrime plates, and Cyto3D assays, serving academic researchers, pharma/biotech drug discovery teams, and cell-therapy biomanufacturers globally via direct sales, distribution partners, and a Sartorius global distribution partnership.

What TheWell Bioscience does

TheWell Bioscience, founded in 2015 and headquartered in Monmouth Junction, New Jersey, is a privately-held biotechnology company (1–10 employees) that develops and sells a proprietary xeno-free (animal origin-free) hydrogel platform for 3D cell culture. Its core product family, VitroGel, is a synthetic, biofunctional extracellular matrix mimic offered in ready-to-use formulations (ORGANOID, STEM, MSC, HEK293, NEURON, EMT) and tunable variants with mechanical stiffness from 10 to 20,000+ Pa and functional ligands (RGD, COL, MMP, IKVAV, YIGSR). The platform is complementary with VitroINK bioinks for 3D bioprinting, RocketCell xeno-free media for organoids/iPSCs/NSCs/hMSCs, CytoGrow recombinant growth factors, VitroPrime culture plates engineered for 3D workflows, and Cyto3D live-dead assay kits, forming an end-to-end xeno-free workflow across hydrogel, media, growth factor, vessel, and downstream analysis layers.

Revenue is generated through three streams: (1) direct sales of consumable products (hydrogels, bioinks, media, growth factors, plates, assay kits) via an e-commerce storefront and direct phone/email ordering with quote-based (non-public) pricing; (2) global distribution through Sartorius Group, which acquired a minority equity stake in April 2024 alongside a cooperation agreement; and (3) international sales through a regional distributor network listed on the company website. Custom solutions services provide additional professional-services revenue for specialized research needs. The company sells to academic researchers (e.g., University of Graz, University of Manchester, Temple University), pharmaceutical/biotech drug discovery teams, stem cell and cell-therapy biomanufacturers, lab-automation/high-throughput screening users, and 3D bioprinting researchers, with adoption evidenced by 370+ peer-reviewed publications citing the products.

TheWell Bioscience firmographics

Firmographics
Name
TheWell Bioscience
Legal name
TheWell Bioscience Inc.
Website
https://thewellbio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
TheWell Bioscience is a privately-held New Jersey biotech that develops and sells an end-to-end xeno-free 3D cell culture platform, including VitroGel hydrogels, VitroINK bioinks, RocketCell media, CytoGrow growth factors, VitroPrime plates, and Cyto3D assays, serving academic researchers, pharma/biotech drug discovery teams, and cell-therapy biomanufacturers globally via direct sales, distribution partners, and a Sartorius global distribution partnership.
Ownership category
akta.pro rank

TheWell Bioscience industry classification

Industry
Product category
3D Cell Culture Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Xeno-free hydrogels
  • 3D cell culture reagents
  • Organoid culture media
  • Biofunctional bioinks
  • Cell culture plates

Where TheWell Bioscience is headquartered

Location

Headquarters

HQ city
Monmouth Junction
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TheWell Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Hydrogel and Bioink Product Sales: TheWell Bioscience generates revenue primarily through the direct sale of its proprietary xeno-free hydrogel products (VitroGel®), bioinks (VitroINK®), culture media (RocketCell™), culture vessels (VitroPrime™), growth factors (CytoGrow™), assay kits, and cell recovery solutions. Products are sold via e-commerce, direct sales, and distributor networks globally.
  2. Distribution Agreement Revenue (Sartorius): Sartorius Group distributes TheWell Bioscience's products globally under a cooperation agreement, providing TheWell with expanded market reach and revenue from distribution arrangements.
  3. Custom Solutions Services: The company offers custom solutions services for specialized research needs, indicating revenue from service engagements alongside product sales.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

TheWell Bioscience product offering

Product offering

Core offering

TheWell Bioscience develops, manufactures, and sells an end-to-end, xeno-free (animal origin-free) 3D cell culture platform built around its proprietary VitroGel® biofunctional hydrogel technology. The product portfolio spans hydrogels (VitroGel®), 3D bioprinting bioinks (VitroINK®), xeno-free culture media (RocketCell™), recombinant growth factors (CytoGrow™), culture plates and vessels (VitroPrime™), live/dead assay kits (Cyto3D®), cell/organoid recovery solutions, and assay kits for angiogenesis, cell invasion, and glioblastoma research.

Product overview

TheWell Bioscience offers an end-to-end, xeno-free 3D cell culture platform consisting of multiple integrated product families. The core offering centers on VitroGel® hydrogels—a range of animal-free, biofunctional hydrogel systems for 3D cell culture available in ready-to-use and tunable formulations. Complementary products include VitroINK® bioinks for 3D bioprinting, RocketCell™ xeno-free culture media for diverse cell types (organoids, iPSCs, NSCs, hMSCs), CytoGrow™ recombinant growth factors and proteins, VitroPrime™ culture plates and vessels optimized for 3D workflows, and Cyto3D® downstream analysis reagents. The platform is designed for applications including organoid culture, stem cell scale-up, cancer research, drug discovery, lab automation, and biomanufacturing. The company positions itself as an all-in-one xeno-free biofunctional platform for precision medicine, cell therapy, and biomanufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • VitroGel®: Xeno-free biofunctional hydrogel system for 3D cell culture applications including organoids, stem cells, and bioprinting
  • VitroINK®
  • RocketCell™
  • VitroPrime™
  • CytoGrow™
  • Cyto3D®

Products and services

  • VitroGel® Hydrogel System Xeno-free, biofunctional hydrogel matrix that mimics natural extracellular matrix for 3D cell culture. Available in ready-to-use variants (ORGANOID, STEM, MSC, HEK293, NEURON, EMT) and tunable variants (3D, RGD, COL, MMP, IKVAV, YIGSR) with adjustable mechanical strength and functional ligands. Enables 3D cell culture assays in less than 20 minutes.
  • VitroINK® Bioinks Xeno-free, biofunctional bioink for 3D bioprinting that prints without UV, heat curing, or chemical cross-linking. Available in multiple functional ligand variants (3D, RGD, COL, MMP, IKVAV, YIGSR) with corresponding starter kits, mixing kits, nozzle tips, and needle tips.
  • RocketCell™ Xeno-Free Culture Media Portfolio of xeno-free 3D cell culture media supporting diverse cell culture applications including organoids, iPSCs, NSCs, and hMSCs. Includes specialized media for organoid culture, iPSC expansion and differentiation, MSC culture, and neural stem cell applications.
  • CytoGrow™ Recombinant Growth Factors and Proteins Portfolio of premium-grade recombinant proteins including growth factors (EGFs, FGFs, PDGFs, TGFs, VEGFs, IGFs, interferons, interleukins), extracellular matrix proteins (fibronectin, vitronectin), and accessory proteins for cell culture applications requiring bioactivity and lot-to-lot consistency.
  • VitroPrime™ Culture Plates and Vessels

Quantifiable outcome

  • Complete ECM dissociation within 2 minutes with VitroGel Organoid Recovery Solution vs. over an hour for conventional alternatives
  • +3 more outcomes

Companies that use TheWell Bioscience

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles5 records

TheWell Bioscience technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

TheWell Bioscience partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • PeptiGrowth Inc.coreGTM or Marketing Partner · 7 January 2026TheWell Bioscience and PeptiGrowth entered into a Marketing Collaboration Agreement to jointly promote complementary cell culture technologies. The partnership combines TheWell's xeno-free VitroGel® hydrogel system with PeptiGrowth's synthetic peptide growth factors to offer a complete xeno-free workflow solution for researchers and biomanufacturers in global life science markets.
  • Sartorius GroupcoreChannel Partner/ Reseller/ Distributor · 9 April 2024Sartorius Group entered into a cooperation agreement and minority shareholding investment in TheWell Bioscience. Under the agreement, Sartorius distributes TheWell Bioscience's animal-free hydrogels and bioinks globally, aiming to improve predictions in drug discovery. The partnership combines Sartorius's global distribution reach with TheWell's xeno-free hydrogel technology. Legal advisory was provided by Hogan Lovells for the cross-border transaction.
  • Dr. Eva Roblegg's Group, University of GrazminorStrategic or Co-development PartnerAcademic research collaboration where Dr. Roblegg's group at the University of Graz used VitroGel® to develop an advanced in vitro vascularized intestinal model including macrovascular endothelium, published in Molecular Pharmaceutics.
  • Breast Biology Group, University of ManchesterminorStrategic or Co-development PartnerAcademic collaboration with the Breast Biology Group at the University of Manchester's Breast Centre to develop a novel preclinical explant model of the normal human breast using VitroGel® RGD, funded by Prevent Breast Cancer and published in the Journal of Mammary Gland Biology and Neoplasia.
  • PAL Lab, Temple UniversityminorStrategic or Co-development PartnerThe PAL Lab at Temple University, led by Ajay Pal, Ph.D., initiated research on VitroGel® NEURON for spinal cord injury repair applications.
  • Hogan LovellsminorOthersHogan Lovells provided legal advisory services to Sartorius Group for the cooperation agreement and minority shareholding in TheWell Bioscience, handling multiple legal and strategic considerations for the cross-border transaction.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

TheWell Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Corning Incorporated: Corning manufactures Matrigel, the dominant animal-derived ECM benchmark that TheWell's VitroGel platform directly competes against in 3D cell culture and organoid applications. Comparable because Corning also produces plastic labware, cell culture vessels, and bioprocess consumables, serving overlapping pharma and academic customers.
  • Thermo Fisher Scientific: Thermo Fisher offers Gibco cell culture media, growth factors, and 3D culture reagents across its life sciences portfolio. Comparable because it sells overlapping reagents and consumables to the same pharma, biotech, and academic researchers that TheWell targets, with far broader bundling and distribution leverage.
  • Merck KGaA (MilliporeSigma): MilliporeSigma supplies ECM hydrogels, cell culture media, and bioprocess reagents under the Sigma-Aldrich brand. Comparable because it serves the same 3D cell culture, organoid, and cell therapy manufacturing markets with a much larger commercial and regulatory footprint.

Direct peers

  • STEMCELL Technologies: STEMCELL Technologies develops specialized cell culture media, reagents, and tools for stem cell, organoid, and immunology research. Comparable because it targets the same life sciences researcher customer base with overlapping product categories (media, matrices, differentiation kits) and competes head-to-head with RocketCell and VitroGel.
  • BICO (CELLINK): BICO, through CELLINK and its subsidiaries, provides bioinks, 3D bioprinters, and tissue engineering consumables. Comparable because it offers VitroINK's direct competition in xeno-free bioinks and operates in overlapping 3D bioprinting and tissue engineering customer segments.
  • Advanced BioMatrix: Advanced BioMatrix manufactures collagen-based, hyaluronic acid, and synthetic ECM hydrogels for 3D cell culture and bioprinting. Comparable because it sells directly overlapping hydrogel and bioink products targeting the same 3D cell culture and tissue engineering researchers.
  • Reprocell: Reprocell provides stem cell products, 3D cell culture reagents, and custom bioassay services to pharma and academic researchers. Comparable because it sells directly competing cell culture matrices and reagents to the same iPSC, organoid, and drug discovery customer segments.

Emerging players

  • TissUse: TissUse develops multi-organ-on-chip and microphysiological systems for drug testing and disease modeling. Comparable because it serves overlapping preclinical researchers using 3D cell models and complements or competes with organoid-based workflows that VitroGel enables.
  • Organovo Holdings: Organovo develops 3D bioprinted human tissue models for drug discovery and therapeutic applications. Comparable because it operates in the 3D bioprinting and tissue engineering space served by VitroINK and intersects with TheWell's organoid and tissue modeling customer base.

Others

  • PeptiGrowth: PeptiGrowth develops synthetic peptide growth factors for cell culture and regenerative medicine. Comparable as an ecosystem partner through the 2026 marketing collaboration with TheWell, addressing overlapping stem cell and cell therapy manufacturing customers seeking a fully xeno-free workflow.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

TheWell Bioscience social profiles

Digital presence

TheWell Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TheWell Bioscience leadership team

Management profile

Number of profiles

Profiles1 record

TheWell Bioscience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TheWell Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheWell Bioscience

What does TheWell Bioscience do?

TheWell Bioscience develops, manufactures, and sells an end-to-end, xeno-free (animal origin-free) 3D cell culture platform built around its proprietary VitroGel® biofunctional hydrogel technology. The product portfolio spans hydrogels (VitroGel®), 3D bioprinting bioinks (VitroINK®), xeno-free culture media (RocketCell™), recombinant growth factors (CytoGrow™), culture plates and vessels (VitroPrime™), live/dead assay kits (Cyto3D®), cell/organoid recovery solutions, and assay kits for angiogenesis, cell invasion, and glioblastoma research.

Is TheWell Bioscience a public or private company?

TheWell Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was TheWell Bioscience founded?

TheWell Bioscience was founded in 2017. It employs 11 to 50 people.

Where is TheWell Bioscience based?

TheWell Bioscience is headquartered in Monmouth Junction, United States, in the North America region.

How does TheWell Bioscience make money?

Three revenue lines are on record. Hydrogel and Bioink Product Sales are the primary driver. The others are distribution Agreement Revenue (Sartorius) and custom Solutions Services.

Who are TheWell Bioscience's main competitors?

Broad incumbents on record are Corning Incorporated, Thermo Fisher Scientific and Merck KGaA (MilliporeSigma). Direct peers are STEMCELL Technologies, BICO (CELLINK), Advanced BioMatrix and Reprocell. Emerging players are TissUse and Organovo Holdings. PeptiGrowth is listed as an others.

Does TheWell Bioscience have an API?

No public API is recorded for TheWell Bioscience.

What industry is TheWell Bioscience in?

TheWell Bioscience's product category is 3D Cell Culture Reagents. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTheWell Bioscience Launches RocketCell™ AOF B27-Like, N2-Like, and N2B27-Like Supplements, Advancing NAMs and Future GMP DevelopmentTheWell Bioscience launched RocketCell S1, S2, and S3 animal origin-free supplements for stem cell and organoid research. The supplements are for research use only, with GMP-grade versions planned for future biomanufacturing and clinical translation.PR NewswireTheWell Bioscience Launches RocketCell™ Cell Viability Enhancer to Improve Cell Recovery, Survival, and Expansion Following Passaging, Cryopreservation, and Organoid HarvestingTheWell Bioscience has launched RocketCell™ Cell Viability Enhancer (1000X), a next-generation cell recovery reagent designed to maximize cell survival and proliferation following passaging, cryopreservation, and organoid harvesting. The proprietary formulation combines ROCK inhibitors with small molecules supporting cellular metabolism, demonstrating 70-80% higher organoid recovery and 7-8 fold greater iPSC recovery in internal validation studies compared to conventional workflows. The product is now available in 50 μL and 500 μL formats as part of the company's expanding portfolio of xeno-free cell culture technologies.PR NewswireTheWell Bioscience Launches Universal Xeno-Free Organoid Medium to Standardize Workflows and Reduce CostsTheWell Bioscience launched RocketCell Organoid Xeno-Free Essential-Core Medium, a chemically defined, universal organoid culture medium. It consolidates multiple media components into one, aiming to reduce costs and variability while supporting scalability. The product is available now.openPR.comLeading Companies Enhancing Their Presence in the Trypsin-EDTA Solution for Cell Dissociation MarketThe Business Research Company published a market analysis projecting the trypsin-EDTA solution for cell dissociation market to reach $2.03 billion by 2030, growing at a compound annual growth rate of 8.8%, driven by rising demand for cell-based therapies and increased biopharmaceutical manufacturing scale-up. In June 2024, Swedish Orphan Biovitrum AB (Sobi) acquired US-based CTI BioPharma Corp. to strengthen its rare-disease and hematology portfolio with a differentiated commercial-stage myelofibrosis treatment. Additionally, TheWell Bioscience launched the VitroGel Organoid Recovery Solution in February 2023, enabling complete ECM dissociation within 2 minutes compared to over an hour for conventional alternatives.openPR.comSegmentation, Major Trends, and Competitive Overview of the Cell Culture Plates MarketThe cell culture plates market is projected to grow to $3.09 billion by 2030, representing a compound annual growth rate of 6.1%, driven by demand for advanced cell culture models, regenerative medicine funding, and automated laboratory workflows. In May 2025, Brookfield Corporation and Quebec Deposit and Investment Fund jointly acquired US-based Antylia Scientific for an undisclosed sum to strengthen their presence in the life sciences sector. Additionally, TheWell Bioscience launched the VitroPrime Spread-Attach Plates in May 2024, designed for hydrogel-based 3D and 2D cell cultures targeting high-throughput research workflows.PR NewswireTheWell Bioscience Launches RocketCell™ hMSC Xeno-Free Complete Growth Medium for Robust and Reproducible Expansion of Human Mesenchymal Stem CellsTheWell Bioscience announced the launch of RocketCell™ hMSC Xeno-Free Complete Growth Medium, a chemically defined, xeno-free medium designed for high-performance expansion of human mesenchymal stem cells and exosome production across research and cell therapy manufacturing workflows. The product addresses variability and regulatory complexity issues associated with traditional serum-based MSC culture systems by eliminating animal-derived inputs. With the global MSC therapeutics market projected for significant growth, scalable and defined expansion platforms like RocketCell™ are positioned to support translational pipelines and commercial manufacturing.PR NewswireTheWell Bioscience Launches VitroPrime™ 3D Culture and Imaging Plate for Organoid and 3D Cell Culture WorkflowsTheWell Bioscience announced the launch of VitroPrime™ 3D Culture and Imaging Plate, a next-generation cell culture product engineered for organoid and advanced 3D cell culture workflows. The plate features a zero-disruption design with sample-locking architecture and passive media exchange, enabling long-term culture, fixation, immunofluorescence staining, and high-resolution imaging to be performed in a single vessel without sample transfer. The product is currently available in 6-, 12-, and 96-well formats and integrates with the company's existing VitroGel® hydrogels, RocketCell™ media, and other platform components.PR NewswireTheWell Bioscience Unveils RocketCell™ 3D iPSC Xeno-Free Complete Growth Kit: A Comprehensive Xeno-Free Ecosystem for Scalable iPSC ExpansionTheWell Bioscience has commercially launched two products in its RocketCell™ line—the 3D iPSC Xeno-Free Complete Growth Kit and the iPSC Xeno-Free Growth Medium—designed to address scalability and workflow challenges in 3D stem cell culture. The complete growth kit combines the company's VitroGel® STEM hydrogel with defined growth media in a ready-to-use system that supports up to 10 times higher cell density than traditional 2D culture methods. Both products, enabling a weekend-free workflow for researchers, are now available for purchase.PR NewswireTheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture SolutionsTheWell Bioscience Inc. and PeptiGrowth Inc. announced a Marketing Collaboration Agreement to jointly promote complementary cell culture technologies for stem cell culture, organoid development, and cell therapy manufacturing. The partnership combines TheWell's xeno-free VitroGel hydrogel system with PeptiGrowth's synthetic peptide growth factors to offer a full xeno-free workflow solution for researchers and biomanufacturers. The companies aim to broaden awareness and adoption of their integrated platforms in global life science markets.PR NewswireTheWell Bioscience Launches VitroGel® NEURON, a First-Of-Its-Kind Synthetic Hydrogel for Superior 3D, 2D Neuronal Cell Culture and BeyondTheWell Bioscience Inc. announced the launch of VitroGel® NEURON, a first-of-its-kind synthetic xeno-free hydrogel designed for both 3D and 2D neuronal cell culture, developed after more than five years of dedicated R&D. The product overcomes limitations of animal-derived matrices by supporting 3D neuron outgrowth and network formation, and also functions as an injectable carrier for neuron-based cell therapy and regenerative medicine applications. The company positions this launch as a pivotal step advancing its 3D cell culture platform for neurobiology, disease modeling, drug screening, and neuropharmacology research.